Circle Pharma's Novel Cyclin Inhibitor Shows Promise Against E2F-Driven Cancers in Nature Study
核心洞察
Circle Pharma (搜索)'s CID-078, a first-in-class oral cyclin A (搜索)/B RxL inhibitor, demonstrated robust anti-tumor activity in preclinical models, including chemotherapy-resistant small cell lung cancer (搜索) xenografts.
The research published in Nature reveals a dual mechanism where the inhibitor blocks cyclin A (搜索)-E2F (搜索) interactions causing DNA damage, then disrupts cyclin B (搜索)-Myt1 (搜索) interactions forcing damaged cells through division to trigger death.
The oral macrocycle therapy targets historically undruggable cyclins and shows particular promise for E2F (搜索)-driven cancers including small cell lung cancer (搜索), triple-negative breast cancer (搜索), and tumors with RB1 (搜索) alterations.
Circle Pharma (搜索) has published groundbreaking research in Nature demonstrating the robust preclinical anti-tumor activity of its first-in-class oral cyclin A (搜索)/B RxL inhibitor, CID-078, which targets historically undruggable proteins to selectively kill E2F (搜索)-high tumor cells. The orally bioavailable macrocycle is currently advancing through Phase 1 clinical development for patients with advanced solid tumors (搜索).
Novel Dual Mechanism Targets Cell Cycle Dysregulation
The research, conducted in collaboration with scientists from Dana-Farber Cancer Institute, Harvard Medical School, the University of Texas Southwestern Medical Center, and the University of Oxford, reveals a sophisticated dual mechanism of action. In preclinical models, cyclin A (搜索)/B RxL inhibitors first blocked the cyclin A-E2F (搜索) interaction, triggering aberrant sustained E2F activity, DNA damage, and replication stress. Subsequently, the inhibitors disrupted the cyclin B (搜索)-Myt1 (搜索) interaction, removing a critical safety brake and forcing damaged tumor cells through division, ultimately causing tumor cell death.
"These findings build upon previous work and reveal additional gain-of-function mechanisms through which cyclin A (搜索)/B RxL inhibition triggers apoptosis in cancer cells, further supporting this approach for E2F (搜索)-driven cancers, such as cancers with RB1 (搜索) alterations," said Matthew G. Oser, M.D., Ph.D., senior author of the publication and associate professor of medicine at Dana-Farber Cancer Institute and Harvard Medical School.
Targeting Historically Undruggable Proteins
Cyclins A and B function as master regulators of the cell cycle by binding to and activating their catalytic partners, the cyclin-dependent kinases (CDKs (搜索)). Cancers driven by high E2F (搜索) activity, such as small cell lung cancer (搜索) (SCLC) and other tumors with RB1 (搜索) alterations, have an overactive cell cycle that leads to uncontrolled tumor cell proliferation. The research demonstrates that CID-078 can potently and selectively disrupt protein-to-protein interactions between cyclins A and B and their key substrates and modulators, including E2F and MYT1 (搜索).
The therapeutic approach shows particular promise for E2F (搜索)-driven cancers, including nearly all small cell lung cancers, up to half of triple-negative breast cancers, and subsets of other solid tumors with RB1 (搜索) alterations. Preclinical studies demonstrated the ability of cyclin A (搜索)/B RxL inhibitors to cause single-agent tumor regressions in multiple in vivo models, including chemotherapy-resistant SCLC patient-derived xenograft models.
Clinical Development and Platform Technology
CID-078 represents the lead program from Circle Pharma (搜索)'s proprietary MXMO™ platform, which overcomes key challenges in macrocycle drug development by enabling the creation of intrinsically cell-permeable and orally bioavailable therapies. A multi-center Phase 1 clinical trial (NCT06577987) is currently enrolling patients with advanced solid tumors (搜索) harboring RB1 (搜索) alterations.
"We are excited to have the novel biology and compelling anti-cancer effects of the cyclin A (搜索)/B RxL inhibitors developed at Circle recognized within the broader scientific community through this publication in Nature," said David J. Earp, J.D., Ph.D., president and chief executive officer of Circle Pharma (搜索). "This work underscores the capabilities of our MXMO™ platform to generate oral, cell-permeable macrocycle therapies, such as CID-078, including for historically undruggable targets such as cyclins."
The research highlights the potential of macrocycle therapeutics to access previously undruggable targets, offering new therapeutic possibilities for patients with difficult-to-treat cancers. Circle Pharma (搜索)'s approach addresses limitations of other therapeutic modalities by creating oral, cell-permeable compounds that can effectively target intracellular protein-protein interactions.